If you will be a 2nd or 3rd year cardiology fellow this July and are interested in Heart Failure, this fellows program is for you! A bootcamp will kick off the 32nd Annual San Diego Symposium in beautiful and sunny San Diego!
sandiegoheartfailure.com/sup…
See link above for the full program and see attached image for details on how to apply for a travel grant! Applications should be sent to, @DrHilaryShapiro at hashapiro@health.ucsd.edu.
(1/14) 🚨I had the privilege of providing commentary on the Phase 2 #coramitug trial at #AHA25. The headline was that patients who received high-dose (60 mg/kg) coramitug had significant reductions in NT-proBNP at 1 year compared with placebo. So it’s an unequivocal win, right? The full story is a bit more complicated…🤔
Happy to share our work focusing on a patient centered outcome for 🫀transplant patients. DCD recipients had similar 1-year days alive outside the hospital (DAOH) as DBD recipients - further supporting the use of DCD in txp 👥🫀📄 sciencedirect.com/science/ar…
On behalf of my course co-directors @RajeevCMohan@UreyTony and I, we are thrilled to be hosting our first-ever joint Scripps/UCSD Cardio-Onc and Cardiomyopathies Conference. Join us in La Jolla on Oct 5 🗓️
Register here: scripps.org/events/cardiomyo…
NEW HFSA Endorsed Meeting: Cardiac Amyloidosis: Diagnosis and Novel Therapeutics in 2024
Date: September 19, 2024
Location: NYU Langone Health, New York
CE Credits: 7.75
Learn more >> hfsa.org/event/cardiac-amylo…
Congratulations to the UC San Diego Cardiology Heart Transplant Program on being named an INTERLINK ELITE program!
The program was also awarded INTERLINK's 2024 Chairman's Award as the #1 performing program for heart transplant in their Programs of Excellence network!
Is apical sparing on echo sufficient for the diagnosis of cardiac amyloidosis? In this multicenter study, we identified 544 patients with CA and 200 controls (suspicion for CA but ruled out for CA), as well as 174 healthy subjects. Led by @JSlivnickMDacademic.oup.com/ehjcimaging…
1/ Check out our recent publication in @JCardFail !
The Cardiac Amyloidosis Registry Study (CARS): Rationale, Design and Methodology - onlinejcf.com/article/S1071-…
(1/10) Today the long-awaited full results from the Phase 3 ATTRibute-CM trial were presented @escardio#ESCCongress. We already knew the topline results from last month: Acoramidis made a (big) difference in outcomes! What more did we learn?🤔Let's dig deeper...
Big news in the #amyloidosis world with the release of top line results for the Phase 3 #acoramidis trial, ATTRIBUTE-CM. Main message: It worked! 🍾 A lot of fascinating history behind this story. What else can we learn from the data? Details to follow… (1/14)